Reactions 1664, p3 - 12 Aug 2017 Risk of kidney disease with atazanavir-containing products The risk of chronic kidney disease (CKD) is now included in the product information for two atazanavir- containing medicines in Canada. In the July issue of Health Product InfoWatch, it was reported that this risk had been included in the Canadian Product Monographs (CPMs) for atazanavir/cobicistat (Evotaz) and atazanavir alone (Reyataz). Specifically, the ’Warnings and Precautions’ and ’Adverse Reactions’ sections of the CPMs for these products will include the following key messages for healthcare professionals: CKD has been reported in patients treated with atazanavir (± ritonavir). Some cases resulted in fatal outcomes or requiring haemodialysis. Evotaz and Reyataz should be used with caution, especially in patients with other risk factors for CKD. Health Canada. Evotaz (atazanavir and cobicistat) and Reyataz (atazanavir). Health Product InfoWatch : 7, Jul 2017. Available from: URL: https://www.canada.ca/ content/dam/hc-sc/documents/services/drugs-health-products/medeffect- canada/health-product-infowatch/health-product-infowatch-july-2017/hpiw- ivps_2017-07-eng.pdf 803263661 0114-9954/17/1664-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 12 Aug 2017 No. 1664
Reactions Weekly – Springer Journals
Published: Aug 12, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera